- Class A
- Class B
- Class C
- Others
G-Protein Coupled Receptor (GPCR) Target Market size was USD 3,538.5 million in 2023 and is expected to reach USD 5,391.3 million in 2030, growing at a CAGR of 6.2% during 2024-2030. GPCRs are the largest and most diverse group of membrane receptors in eukaryotes, playing a crucial role in various physiological processes. The market's growth is driven by several factors: increasing prevalence of chronic diseases, rising investment in drug discovery and development, advancements in GPCR research technologies, and the growing focus on personalized medicine. Additionally, the potential of orphan GPCRs as novel drug targets is creating new opportunities for pharmaceutical companies. However, the GPCR targeting market faces challenges such as the complexity of GPCR signalling pathways, high attrition rates in drug development, and the need for more efficient screening technologies.
G-Protein Coupled Receptor (GPCR) Target Market Key Developments:
- In August 2022, Sosei Group Corporation and AbbVie announced a new drug development cooperation and option-to-license agreement to identify, develop, and market small compounds modulating novel G protein-coupled receptor (GPCR) targets linked to neurological illness.
- In December 2022, Sosei Heptares and Eli Lilly launched a drug discovery collaboration to discover, develop, and commercialize small compounds that modify novel G protein-coupled receptor (GPCR) targets related to diabetes and metabolic disorders.
G Protein Coupled Receptor Target Market Summary
Study Period
2024-2030Base Year
2023CAGR
6.2%Largest Market
North-AmericaFastest Growing Market
Asia-PacificG-Protein Coupled Receptor (GPCR) Target Market Dynamics
The GPCR targeting market is experiencing significant growth driven by technological advancements and an increasing understanding of GPCR biology. The emergence of structural biology techniques, such as cryo-electron microscopy, has revolutionized GPCR drug discovery by providing detailed insights into receptor structures and ligand binding mechanisms. This has led to the development of more selective and efficacious GPCR-targeted therapies. Furthermore, the adoption of artificial intelligence and machine learning in drug discovery is accelerating the identification of novel GPCR ligands and potential drug candidates. The market is also seeing a shift towards allosteric modulators and biased agonists, which offer improved safety profiles and reduced side effects compared to traditional orthosteric ligands. Additionally, the growing interest in polypharmacology and multi-target drugs is opening new avenues for GPCR-targeted therapies in complex diseases.
North-America Got Significant Share of
G-Protein Coupled Receptor (GPCR) Target Market Regional Analysis
North America dominates the GPCR targeting market, accounting for the largest share due to the presence of major pharmaceutical companies, high R&D investments, and favorable regulatory environment. The United States, in particular, leads in GPCR drug discovery and development, supported by advanced research institutions and a robust biotech ecosystem. Europe holds the second-largest market share, driven by strong academic research in GPCR biology and increasing collaborations between academia and industry. The Asia Pacific region is poised for substantial growth, fueled by increasing investment in life sciences research, growing pharmaceutical markets in countries like China and India, and the rising prevalence of chronic diseases.
Latin America
Europe
Asia Pacific
Middle East
North America
G Protein Coupled Receptor Target Market Segmentation
By Receptor Type
By Therapeutic Area
- Oncology
- CNS Disorders
- Cardiovascular Diseases
- Metabolic Disorders
- Immunological Disorders
- Respiratory Diseases
- Others
By Drug Type
- Small Molecules
- Biologics
Frequently Asked Questions
The global G-Protein Coupled Receptor (GPCR) Target market size was USD 3,538.5 million in 2023 and is expected to reach USD 5,391.3 million in 2030, growing at a CAGR of 6.2% during the forecast period.
Key drivers include the increasing prevalence of chronic diseases, advancements in GPCR research technologies, rising investment in drug discovery and development, and growing focus on personalized medicine.
Restraints include the complexity of GPCR signalling pathways, high attrition rates in drug development, and challenges in developing selective ligands for closely related receptor subtypes.
The major players in the GPCR targeting market include Pfizer Inc., Merck & Co., Inc., Novartis AG, AstraZeneca plc, and Amgen Inc., among others.
Key Features of the Report
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030).
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies.
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market.
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market.
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenarios.
| 1.Executive Summary |
| 2.Global G Protein Coupled Receptor Target Market Introduction |
| 2.1.Global G Protein Coupled Receptor Target Market - Taxonomy |
| 2.2.Global G Protein Coupled Receptor Target Market - Definitions |
| 2.2.1.Receptor Type |
| 2.2.2.Therapeutic Area |
| 2.2.3.Drug Type |
| 2.2.4.Region |
| 3.Global G Protein Coupled Receptor Target Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global G Protein Coupled Receptor Target Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global G Protein Coupled Receptor Target Market By Receptor Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Class A |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Class B |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Class C |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Others |
| 5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 6.Global G Protein Coupled Receptor Target Market By Therapeutic Area, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Oncology |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. CNS Disorders |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Cardiovascular Diseases |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Metabolic Disorders |
| 6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Immunological Disorders |
| 6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 6.6. Respiratory Diseases |
| 6.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.6.3. Market Opportunity Analysis |
| 6.7. Others |
| 6.7.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.7.3. Market Opportunity Analysis |
| 7.Global G Protein Coupled Receptor Target Market By Drug Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. Small Molecules |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Biologics |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 8.Global G Protein Coupled Receptor Target Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia Pacific (APAC) |
| 8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Middle East and Africa (MEA) |
| 8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Latin America |
| 8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9.North America G Protein Coupled Receptor Target Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 9.1. Receptor Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Class A |
| 9.1.2.Class B |
| 9.1.3.Class C |
| 9.1.4.Others |
| 9.2. Therapeutic Area Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Oncology |
| 9.2.2.CNS Disorders |
| 9.2.3.Cardiovascular Diseases |
| 9.2.4.Metabolic Disorders |
| 9.2.5.Immunological Disorders |
| 9.2.6.Respiratory Diseases |
| 9.2.7.Others |
| 9.3. Drug Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Small Molecules |
| 9.3.2.Biologics |
| 9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.4.1.United States of America (USA) |
| 9.4.2.Canada |
| 10.Europe G Protein Coupled Receptor Target Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 10.1. Receptor Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Class A |
| 10.1.2.Class B |
| 10.1.3.Class C |
| 10.1.4.Others |
| 10.2. Therapeutic Area Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Oncology |
| 10.2.2.CNS Disorders |
| 10.2.3.Cardiovascular Diseases |
| 10.2.4.Metabolic Disorders |
| 10.2.5.Immunological Disorders |
| 10.2.6.Respiratory Diseases |
| 10.2.7.Others |
| 10.3. Drug Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Small Molecules |
| 10.3.2.Biologics |
| 10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Germany |
| 10.4.2.France |
| 10.4.3.Italy |
| 10.4.4.United Kingdom (UK) |
| 10.4.5.Spain |
| 11.Asia Pacific (APAC) G Protein Coupled Receptor Target Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 11.1. Receptor Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Class A |
| 11.1.2.Class B |
| 11.1.3.Class C |
| 11.1.4.Others |
| 11.2. Therapeutic Area Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Oncology |
| 11.2.2.CNS Disorders |
| 11.2.3.Cardiovascular Diseases |
| 11.2.4.Metabolic Disorders |
| 11.2.5.Immunological Disorders |
| 11.2.6.Respiratory Diseases |
| 11.2.7.Others |
| 11.3. Drug Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Small Molecules |
| 11.3.2.Biologics |
| 11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.China |
| 11.4.2.India |
| 11.4.3.Australia and New Zealand (ANZ) |
| 11.4.4.Japan |
| 11.4.5.Rest of APAC |
| 12.Middle East and Africa (MEA) G Protein Coupled Receptor Target Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 12.1. Receptor Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Class A |
| 12.1.2.Class B |
| 12.1.3.Class C |
| 12.1.4.Others |
| 12.2. Therapeutic Area Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Oncology |
| 12.2.2.CNS Disorders |
| 12.2.3.Cardiovascular Diseases |
| 12.2.4.Metabolic Disorders |
| 12.2.5.Immunological Disorders |
| 12.2.6.Respiratory Diseases |
| 12.2.7.Others |
| 12.3. Drug Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Small Molecules |
| 12.3.2.Biologics |
| 12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.GCC Countries |
| 12.4.2.South Africa |
| 12.4.3.Rest of MEA |
| 13.Latin America G Protein Coupled Receptor Target Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 13.1. Receptor Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Class A |
| 13.1.2.Class B |
| 13.1.3.Class C |
| 13.1.4.Others |
| 13.2. Therapeutic Area Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Oncology |
| 13.2.2.CNS Disorders |
| 13.2.3.Cardiovascular Diseases |
| 13.2.4.Metabolic Disorders |
| 13.2.5.Immunological Disorders |
| 13.2.6.Respiratory Diseases |
| 13.2.7.Others |
| 13.3. Drug Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Small Molecules |
| 13.3.2.Biologics |
| 13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Brazil |
| 13.4.2.Mexico |
| 13.4.3.Rest of LA |
| 14. Competition Landscape |
| 14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 14.2.1.Pfizer Inc. |
| 14.2.2.Merck & Co., Inc. |
| 14.2.3.Novartis AG |
| 14.2.4.AstraZeneca plc |
| 14.2.5.Amgen Inc. |
| 14.2.6.Bristol-Myers Squibb Company |
| 14.2.7.Takeda Pharmaceutical Company Limited |
| 14.2.8.Sanofi S.A. |
| 14.2.9.GlaxoSmithKline plc |
| 14.2.10.Roche Holding AG |
| 15. Research Methodology |
| 16. Appendix and Abbreviations |
- Pfizer Inc.
- Merck & Co., Inc.
- Novartis AG
- AstraZeneca plc
- Amgen Inc.
- Bristol-Myers Squibb Company
- Takeda Pharmaceutical Company Limited
- Sanofi S.A.
- GlaxoSmithKline plc
- Roche Holding AG